Tuesday, May 28, 2024

Stocks Going Ex Dividend in June of 2024

Please note that this is a sister publication of WallStreetNewsNetwork ( https://WStNN.com ) and postings will end on this site shortly. Please go to https://WStNN.com for all future posts. 

 The following is a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors interested in the stock trading technique known as “Buying Dividends” or “Dividend Capture.” This strategy involves purchasing stocks before the ex dividend date and selling them shortly after the ex-date at a similar price, while still being eligible to receive the dividend payment.

Although this technique generally proves effective in bull markets and flat or choppy markets, it is advisable to exercise caution and consider avoiding this strategy during bear markets. To qualify for the dividend, it is necessary to buy the stock before the ex-dividend date and refrain from selling it until on or after the ex-date.

However, it is important to note that the actual dividend may not be paid for several weeks, as the payment date can be delayed by up to two months after the ex-date.

For investors seeking a comprehensive list of stocks going ex-dividend in the near future, WallStreetNewsNetwork.com has compiled a downloadable list containing numerous dividend-paying companies. Here are a few examples showcasing the stock symbol, ex-dividend date, periodic dividend amount, and annual yield.

McDonald’s Corporation (MCD)6/3/20241.672.59%
Harley-Davidson, Inc. (HOG)6/5/20240.17251.96%
Bank of America Corporation (BAC)6/7/20240.242.42%
NVIDIA Corporation (NVDA)6/11/20240.010.04%
Macy’s Inc (M)6/14/20240.17373.44%
Southwest Airlines Company (LUV)6/18/20240.182.68%
Main Street Capital Corporation (MAIN)6/21/20240.308.30%
Dillard’s, Inc. (DDS)6/28/20240.250.22%

To access the entire list of over 100 ex-dividend stocks, subscribers will receive an email in the next couple days with the full list. If you are not already a subscriber, you can sign up using the provided signup box below. Don’t miss out on this valuable information, and the best part is that it’s free!

Sign Up for the WStNN Newsletter for Free

Dividend Definitions

To better understand the dividend-related terms, let’s define them:

Declaration date: This refers to the day when a company announces its intention to distribute a dividend in the future.
Ex-dividend date: On this day, if you purchase the stock, you would not be eligible to receive the upcoming dividend. It is also the first day on which a shareholder can sell their shares and still receive the dividend.
Record date: This marks the day when you must be recorded on the company’s books as a shareholder to qualify for the dividend. Typically, the ex-dividend date is set two business days prior to the record date.
Payment date: This is the day on which the dividend payment is actually made to the eligible shareholders. It’s important to note that the payment date can be as long as two months after the ex-date.

Before implementing the “Buying Dividends” technique, it is crucial to reconfirm the ex-dividend date with the respective company to ensure accuracy and avoid any unexpected changes.

In conclusion, being aware of the stocks going ex-dividend can be advantageous for traders and investors employing the “Buying Dividends” strategy. WallStreetNewsNetwork.com provides a convenient resource to access a comprehensive list of such stocks, allowing individuals to plan their investment decisions effectively. Remember to stay informed and consider market conditions before employing any investment strategy.

Disclosure: Author owns MCD, HOG, BAC, and MAIN.

5 Under 10: Low Share Price, Debt Free, Lots of Cash

Please note that this is a sister publication of WallStreetNewsNetwork ( https://WStNN.com ) and postings will end on this site shortly. Please go to https://WStNN.com for all future posts. 

 It is amazing that there are still debt free stocks with lots of cash and trade for less than $10 per share. The following are five of these low priced stocks with lots of cash per share, and no or very low debt. Most of them have very low cap stocks and should be considered very speculative.

Green Dot Corporation (GDOT) is a financial technology company headquartered in Austin, Texas, with a mission to transform how people manage their money. Founded in 1999, they’ve grown into a leader in the prepaid debit card market, holding the world’s largest market share by capitalization. However, their reach extends beyond prepaid cards. Green Dot also functions as a payment platform company, powering solutions for well-known brands like Apple Cash, Uber, and Intuit.

Green Dot initially targeted teenagers with their prepaid debit cards, offering a way to shop online safely. They quickly pivoted in 2001 to focus on the “unbanked” and “underbanked” communities, providing essential financial services to those who might not have access to traditional banking options. This focus on financial inclusion has remained a core part of their mission.

Green Dot operates as a “branchless bank,” relying on a network of over 90,000 retail locations across the country for distribution. They’ve also established Green Dot Bank, a subsidiary that’s FDIC-insured, ensuring customer deposits are protected. Green Dot’s proprietary technology allows for fast and efficient electronic payments and money management,providing users with secure and intuitive tools to spend, send, save, and control their finances.

Green Dot trades at an incredibly low 43% of cash per share, and it has no long term debt. 

The stock trades at 5.4 time forward earnings, and has an extremely favorable price to sales ratio of 0.33. It also sells at 58% of book value. 

Long term annual growth estimate of earnings per share over the next five years is 12.9%.

Aeva Technologies, Inc. (AEVA) is a company on the cutting edge of LiDAR technology, a system used in self-driving cars, robotics, and consumer electronics. Their journey began in December of 2016 when Soroush Salehian and Mina Rezk,with experience from Apple and Nikon, founded the company.

In 2017, after securing $3.5 million in funding, Aeva emerged from stealth mode and quickly gained momentum. They secured $45 million in Series A funding from Lux Capital and Canaan Partners, followed by additional investment from strategic partners like Porsche SE and Lockheed Martin.

A significant milestone came in 2021 when Aeva went public through a merger with InterPrivate Acquisition Corp. This merger raised over $560 million and allowed Aeva to begin trading on the NYSE under the ticker symbol AEVA.

Since going public, Aeva has continued to achieve important milestones. They partnered with Fabrinet to manufacture their CoreVision “LiDAR-on-Chip” modules and secured Nikon as their first industrial metrology customer. Notably,Aeva collaborated with TuSimple on the industry’s first fully autonomous drive using their sensor technology.

Their achievements extend beyond the automotive industry. Aeva became the first 4D LiDAR company compatible with Nvidia Drive, a key platform for autonomous vehicles. Additionally, their technology impressed NASA, who contracted Aeva to develop solutions for lunar exploration missions. Most recently, Aeva partnered with SICK AG to provide their 4D LiDAR technology for industrial automation equipment.

Aeva has a price to cash ratio of 0.93. That means that the price of the stock is less than the amount of cash the company has per share. In addition, the company has almost no debt. 

The stock is trading at 83% of book value. Unfortunately, the company is generating negative earnings. Sales growth year over year is up over 25%. 

Atea Pharmaceuticals, Inc. (AVIR) is a biopharmaceutical company dedicated to developing innovative antiviral treatments. Their focus lies on creating oral therapies to address serious viral infections and improve patient outcomes.

The company leverages its expertise in antiviral drug development, nucleos(t)ide chemistry, and virology to discover and advance novel drug candidates. These candidates target single-stranded ribonucleic acid (ssRNA) viruses, a common cause of severe viral diseases. Currently, their pipeline prioritizes treatments for SARS-CoV-2, the virus responsible for COVID-19, and Hepatitis C Virus (HCV).

Atea operates at the clinical stage, which means their drug candidates are undergoing clinical trials to assess their safety and efficacy. Their commitment to efficient and scalable manufacturing ensures potential stockpiling of their medications for future outbreaks.

Beyond just scientific expertise, Atea fosters a culture of diversity, equity, and inclusion within their workforce. They believe this approach fosters innovation and allows employees to contribute their unique perspectives for the benefit of the company and future patients.

Atea trades at only 57% of its cash per share, and is totally debt free. That means that if the company stopped operating today, and all the company’s non-cash assets were totally worthless, investors would almost double their money just from the cash.

However, since this is a biotech company, the burn rate can be high. The burn rate is, in simple terms, the amount of cash the company is spending of its cash on an ongoing basis.

The stock trades at 58% of book value. The company generates negative earnings and hasn’t yet generated sales.

American Well Corporation (AMWL), known simply as Amwell, is a frontrunner in the telehealth industry. They focus on creating digital healthcare solutions that make medical care more accessible and convenient.

Founded in 2006, Amwell offers a comprehensive platform called Amwell Converge. This platform equips healthcare systems, health plans, government agencies, and even universities with the tools they need to provide efficient virtual care. Amwell Converge facilitates a variety of healthcare interactions, including both on-demand and scheduled consultations, ranging from primary and urgent care to specialty consultations like telestroke and telepsychiatry.

Amwell operates across the United States, partnering with over 240 health systems and 55 health plans, collectively reaching over 80 million covered lives. Their reach extends beyond basic consultations as well. Amwell offers Amwell Medical Group, a subscription-based service that connects patients with a network of licensed physicians for ongoing care needs.

Looking beyond the platform itself, Amwell prioritizes partnerships. They collaborate with a wide range of healthcare providers, payers, and innovators to create a comprehensive care ecosystem that seamlessly blends in-person, virtual, and even automated care options. This patient-centered approach aims to improve healthcare outcomes and make quality care more accessible to everyone.

The stock, which has very low debt, sells at 45% of cash, 34% of book value, and has a price sales ratio of 0.55. The company has been generating negative earnings.

ContextLogic Inc. (WISH), better known by its shopping platform Wish, is an e-commerce company that thrives on mobile technology. Established in 2010, they’ve carved a niche for themselves in the online shopping world, particularly in Europe and North America, with a presence in South America and other regions as well.

Wish’s core function is to connect consumers with a vast network of merchants. They utilize a user-friendly mobile app to showcase a wide array of products, often at competitive prices. Their personalized product recommendations and gamified shopping experience have become hallmarks of the Wish platform.

ContextLogic Inc. doesn’t just connect buyers and sellers; they also provide valuable services to their merchants. The company offers marketplace and logistics support, streamlining the process for businesses to reach new customers and efficiently deliver their products. This focus on both sides of the e-commerce equation has been instrumental in Wish’s growth and success.

Headquartered in San Francisco, California, ContextLogic Inc. continues to innovate and expand its reach, making online shopping more accessible and convenient for millions of users worldwide.

The stock has a price to cash ratio of 0.41, a price to book ratio of 0.76, and a price sales ratio of 0.57. The company has been generating negative earnings.

Keep in mind that there are all very low market cap companies that should be considered very speculative.

Disclosure: Author didn’t own any of the above at the time the article was written.

Can Weight Loss Companies Fuel Gains in Your Stock Portfolio?

Please note that this is a sister publication of WallStreetNewsNetwork ( https://WStNN.com ) and postings will end on this site shortly. Please go to https://WStNN.com for all future posts. 

 The past year has seen a surge in the popularity of injectable medications for weight loss. Drugs like Ozempic and Wegovy, both made by Novo Nordisk (NVO), and Zepbound and Mounjaro, which are manufactured by Eli Lilly (LLY), are finding themselves in high demand, despite their hefty price tags and limited insurance coverage.

This trend reflects a growing openness to pharmaceutical solutions for weight management, alongside traditional methods like diet and exercise. These injectable drugs, which mimic natural gut hormones, work by curbing appetite and promoting feelings of fullness. Studies have shown significant weight loss in patients using these medications.

Ozempic and Wegovy are both GLP-1 receptor agonists, targeting a specific hormone that regulates appetite and blood sugar. Ozempic was originally approved for type 2 diabetes, but its weight loss side effects have driven its use in that area as well. Wegovy, on the other hand, is specifically FDA-approved for chronic weight management.

Zepbound, a newcomer to the market, is another GLP-1 receptor agonist with an additional twist. It also targets another gut hormone, GIP, that further enhances feelings of fullness and reduces appetite. Early studies suggest Zepbound may lead to even greater weight loss than Wegovy.

Mounjaro, another Eli Lilly product, joins the party as a dualincretin medication. Like Zepbound, it targets both GLP-1 and GIP receptors, offering similar weight loss benefits. Interestingly, Mounjaro is actually FDA-approved for type 2 diabetes, but like Ozempic, its weight loss effects are driving its use in that area as well. Studies suggest Mounjaro might be as effective as Zepbound in terms of weight loss.

This rise in weight loss injectable use is projected to continue. Analysts predict the weight loss drug market could reach $100 billion by the end of the decade, with millions of patients potentially using these medications. However, challenges remain. The high cost and limited insurance coverage are barriers for many. Additionally, long-term side effects of these medications are still being studied.

While these injectable drugs offer a promising new tool for weight management, they are not a magic bullet. They are most effective when used in conjunction with a healthy diet and exercise program.

Novo Nordisk (NVO) is a global healthcare company headquartered near Copenhagen, Denmark, with a rich history dating back to 1923. Their founding story is intertwined with the discovery of insulin, a revolutionary treatment for diabetes.

The company’s mission is “to drive change to defeat serious chronic diseases,” and they have become a leader in the diabetes care space. They develop and manufacture a wide range of diabetes medications, including injectable insulins and GLP-1 receptor agonists like the popular Ozempic and Wegovy mentioned earlier.

Beyond diabetes, Novo Nordisk is expanding its reach into other chronic diseases. They offer treatments for obesity, such as Wegovy, and medications for hemophilia and other rare blood disorders. Their research and development efforts continue to push boundaries in these areas.

    Novo Nordisk employs over 64,000 people worldwide and distributes its products in over 170 countries.

    The stock trades at 44 times trailing earnings and 31 time forward earnings. Quarterly revenue growth year-over-year was 23.6%, with earning growth over the same period at an incredible 30.7%.

    Novo pays a dividend semi-annually, with an estimated yield of 1.31%. 

    Eli Lilly and Company (LLY), headquartered in Indianapolis, Indiana, boasts a rich heritage dating back to 1876. Founded by Colonel Eli Lilly with a vision to “take what you find here and make it better and better,” the company has established itself as a major player in the pharmaceutical industry.

    Eli Lilly is dedicated to turning science into solutions for a healthier world. Their core focus lies in research and development, with a significant portion of their workforce dedicated to this pursuit. They leverage advancements in biotechnology, chemistry, and genetic medicine to tackle some of the world’s most pressing health challenges.

    The company’s product portfolio is extensive, encompassing medications for a wide range of conditions. Here’s a glimpse into their key areas:

    • Diabetes: Eli Lilly has a strong presence in diabetes care, offering medications beyond the newcomer, Mounjaro,discussed earlier.
    • Oncology: They are actively involved in cancer research and development, producing treatments for various types of cancer.
    • Immunology: Eli Lilly develops medications for autoimmune diseases and other conditions related to the immune system.
    • Pain Management: The company offers a range of pain management solutions.
    • Others: Eli Lilly’s product line also includes medications for neurology, endocrinology, and other therapeutic areas.

    With over 44,000 employees worldwide and a strong emphasis on scientific advancement, Eli Lilly remains a force to be reckoned with in the global pharmaceutical landscape.

    Lilly has a nosebleed high trailing price to earnings ratio of 116; but a bit more reasonable forward P/E of 41.5. Quarterly revenue growth grew 26%, with quarterly earnings per share growth at a superior 66.7% year-over-year. 

    The company pays dividends quarterly and yields 0.67%.

    If you are looking for a non-pharmaceutical investment option, there is WW International (WW).

    WW International, Inc., formerly known as Weight Watchers International, is a global company headquartered in New York City. Founded in 1963 by Jean Nidetch, WW has a long history of helping people achieve weight loss and wellness goals.

    Shifting Focus: Beyond Weight Loss

    Traditionally, WW was known for its weight loss programs, often centered around group meetings and a points-based system for tracking food intake. However, in 2018, the company underwent a significant rebranding, reflecting a shift towards a more holistic approach to health and wellness.

    This move is reflected in their new name, WW, which purposely avoids mentioning weight. Their current programs encompass aspects like fitness, mindset, and overall healthy habits, not just weight loss on the scale.

    WW’s Offerings Today

    WW offers a multi-pronged approach to wellness, with options to suit different needs and preferences:

    • Digital Solutions: Their mobile app and website provide access to tools for tracking food, activity, weight, and sleep. They also offer educational content and motivational support.
    • Coaching: WW provides online or phone coaching for personalized guidance and support.
    • Wellness Workshops: These in-person group meetings, formerly known as Weight Watchers meetings, foster a sense of community and offer guidance on healthy living.

    Financial Performance

    While they have faced challenges in recent years, they remain a major player in the weight management and wellness industry.

    The stock has taken a major hit in the last seven months, dropping from above $13 a share to now less than two dollars a share. 

    The company generated a huge lost for the year; however, it is estimated that it will produce a reasonable profit next year, providing a forward P/E of 7.06.


    Novo and Lilly have already had major gains in their stock price. It remains to be seen it this growth will continue, especially with greater acceptance of their drugs. 

    Hopefully, one of these companies can provide greater weight to your portfolio.

    Disclosure: Author has a small bullish call position in Novo.

    Wednesday, May 22, 2024

    Exploring the Significance of Gold in History and the Economy

      Please note that this is a sister publication of WallStreetNewsNetwork ( https://WStNN.com ) and postings will end on this site shortly. Please go to https://WStNN.com for all future posts. 

    Recently, we posted an article about silver as an investment. Now it’s time for gold.

    Gold has captivated humanity for millennia, with its allure dating back to ancient civilizations. As shiny nuggets were first discovered, gold quickly became a symbol of wealth and power. The scarcity and distinctive properties of gold made it highly prized. This led to the adoption of gold as currency by various cultures across the globe. Gold played a crucial role in shaping economies and trade networks, facilitating commerce and influencing political dynamics.

    The California Gold Rush of the mid-19th century marked a pivotal moment in gold’s history. The discovery of gold nuggets at Sutter’s Mill in 1848 sparked a large migration to the American West, drawing people from all walks of life in search of fortune. The influx of prospectors fueled rapid economic growth and transformed California into a growing economy. 

    Gold is often regarded as a hedge against inflation due to its historical track record of preserving wealth during times of economic uncertainty. When inflation rises, the purchasing power of fiat currencies decreases. This leads investors to seek assets that can retain their value. Gold has demonstrated its ability to act as a store of value over centuries, making it a popular choice for investors looking to protect their wealth from the devastating effects of inflation.

    During periods of high inflation, the price of gold tends to increase as investors flock to it as a safe haven asset. Gold’s scarcity and tangible nature contribute to its appeal as a hedge against inflation. Unlike fiat currencies, which can be subject to manipulation by central banks. The gold supply is limited, providing a natural defense against currency devaluation. Additionally, gold has inherent value and is not reliant on the performance of financial markets, making it a reliable hedge during times of economic turbulence.

    Gold’s status as a globally recognized currency adds to its appeal as an inflation hedge. This universal acceptance of gold allows its liquidity as a hedge against inflation in various economic environments. Central banks and institutional investors often allocate a portion of their portfolios to gold to mitigate the effects of inflation and safeguard their wealth over the long term.

    Some of the major U.S. gold mining companies are:

    CompanyCompany SymbolPrice to BookPEGPEPrice to SalesForward PEYield
    Coeur Mining IncCDE1.7NAna2.216.260
    i-80 Gold CorpIAUX0.89NANA7.24NA0
    Newmont CorpNEM1.550.79NA3.8214.482.56%
    Novagold Resources Inc.NG25.84NANANANA0.00%
    Royal Gold, Inc.RGLD2.797.4933.6913.3222.461.32%
    SSR Mining IncSSRM0.32NANA0.7615.55.45%

    Throughout history, gold has retained its status as a safe haven asset and a hedge against economic uncertainty. Its value surged during times of crisis, such as wars, financial crises, and geopolitical tensions. In the modern era, gold continues to play a crucial role in investment portfolios and central bank reserves, providing stability in volatile markets. Its timeless appeal as a store of value ensures that gold remains a cornerstone of global finance and culture.

    Stay ahead of the game and subscribe to our newsletter now to unlock the hottest investment opportunities!

    Subscribe Here

    Disclosure: Author had no positions in any of the above at the time the article was written.